Paclitaxel/carboplatin with or without sorafenib in the first-line treatment of patients with stage III/IV epithelial ovarian cancer: A randomized phase II study of the Sarah Cannon Research Institute.
Dana Shelton Thompson
No relevant relationships to disclose
B. Stephens Dudley
No relevant relationships to disclose
John A. Bismayer
No relevant relationships to disclose
Victor G. Gian
No relevant relationships to disclose
William McIver Merritt
No relevant relationships to disclose
Robert C. Whorf
No relevant relationships to disclose
Howard A. Burris
No relevant relationships to disclose
John D. Hainsworth
No relevant relationships to disclose